Tapentadol Depot Krka
Extended-release opioid analgesic for severe chronic pain
Tapentadol Depot Krka is a strong opioid pain medication used for the treatment of severe chronic pain in adults and children over 6 years of age when other pain relievers are not sufficient. It works through a unique dual mechanism — acting on opioid receptors and inhibiting norepinephrine reuptake — to provide sustained 12-hour pain relief. This is a prescription-only, controlled-substance medication that requires careful medical supervision due to the risk of addiction, respiratory depression, and potentially life-threatening interactions.
Quick Facts
Key Takeaways
- Tapentadol Depot Krka is a strong opioid prescribed for severe chronic pain that does not respond to non-opioid analgesics. It should only be used under close medical supervision.
- The extended-release tablets must be swallowed whole every 12 hours. Never crush, chew, or break them, as this can cause a life-threatening overdose from rapid drug release.
- Tapentadol has a dual mechanism of action (mu-opioid receptor agonism + norepinephrine reuptake inhibition), which may reduce certain opioid-related side effects compared to pure opioids.
- Common side effects include nausea, constipation, dizziness, and drowsiness. Serious risks include respiratory depression, addiction, and serotonin syndrome when combined with serotonergic drugs.
- Do not combine with MAO inhibitors, benzodiazepines, alcohol, or other CNS depressants without medical guidance, as these combinations can be fatal.
What Is Tapentadol Depot Krka and What Is It Used For?
Tapentadol Depot Krka contains the active substance tapentadol, which belongs to the class of opioid analgesics. Unlike traditional opioids such as morphine or oxycodone, tapentadol has a unique dual mechanism of action known as MOR-NRI (mu-opioid receptor agonism combined with norepinephrine reuptake inhibition). This means it works through two complementary pain pathways in the central nervous system simultaneously.
The mu-opioid receptor agonism component modulates pain signals in the brain and spinal cord by activating the same receptors targeted by other opioids. The norepinephrine reuptake inhibition component enhances the descending pain inhibitory pathways, which are the body's natural pain-suppression system. By engaging both mechanisms, tapentadol can provide effective analgesia while potentially causing fewer gastrointestinal side effects (such as constipation and nausea) compared to equipotent doses of traditional pure mu-opioid agonists.
The extended-release (depot) formulation is specifically engineered to release tapentadol gradually over approximately 12 hours, providing steady, round-the-clock pain relief. This makes it suitable for chronic pain conditions that require continuous, long-term opioid therapy. Tapentadol Depot Krka is indicated for:
- Adults: Treatment of severe chronic pain that can only be adequately managed with opioid analgesics.
- Children over 6 years and adolescents: Treatment of severe chronic pain requiring opioid-level analgesia, under careful medical supervision.
It is important to understand that tapentadol is reserved for patients whose pain is genuinely severe and has not responded adequately to non-opioid treatments. It is not intended for mild or intermittent pain, post-operative pain management (where immediate-release formulations may be more appropriate), or as a first-line analgesic. Your prescribing physician will have determined that the benefits of tapentadol therapy outweigh the substantial risks associated with opioid use.
The medication is manufactured by KRKA, d.d., Novo mesto, a major European pharmaceutical company headquartered in Slovenia. It is available in multiple strengths (50 mg, 100 mg, 150 mg, 200 mg, and 250 mg) to allow individualized dosing.
What Should You Know Before Taking Tapentadol Depot Krka?
Contraindications
You must not take Tapentadol Depot Krka if any of the following apply to you:
- Allergy to tapentadol or any other ingredient in the tablets (including hypromellos, microcrystalline cellulose, colloidal anhydrous silicon dioxide, magnesium stearate, lactose monohydrate, titanium dioxide, or iron oxides).
- Severe respiratory depression — if your breathing is dangerously slow or shallow (respiratory depression, hypercapnia). Tapentadol further suppresses the respiratory drive and can cause fatal respiratory arrest in these patients.
- Asthma in an uncontrolled setting or acute asthma attacks, particularly in the absence of monitoring equipment or resuscitative measures.
- Paralytic ileus — a condition where the bowel has stopped functioning. Opioids slow gut motility further and can worsen this dangerous condition.
- Acute intoxication with alcohol, sleeping pills, other opioid analgesics, or psychotropic drugs (medications that affect mood and emotions). The combination of CNS depressants with tapentadol can be lethal.
- Concurrent use of MAO inhibitors or use within the last 14 days. The interaction between tapentadol and MAO inhibitors can cause serotonin syndrome, hypertensive crisis, or other life-threatening reactions.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Tapentadol Depot Krka if any of the following conditions apply:
- Respiratory conditions: Slow or shallow breathing, chronic obstructive pulmonary disease (COPD), cor pulmonale, or other conditions that compromise respiratory function. Tapentadol may cause life-threatening respiratory depression, particularly in elderly or debilitated patients.
- Raised intracranial pressure or impaired consciousness: Including head injury, brain tumors, or reduced level of consciousness. Opioids can obscure the clinical course of patients with head injuries and increase intracranial pressure.
- Liver disease: Patients with moderate hepatic impairment require dose adjustment. Patients with severe hepatic impairment should not take this medication.
- Kidney disease: Patients with severe renal impairment should not take these tablets. No dose adjustment is needed for mild or moderate renal impairment.
- Pancreatic or biliary tract disease: Including pancreatitis. Opioids can cause spasm of the sphincter of Oddi, worsening biliary conditions.
- Seizure disorders or epilepsy: Tapentadol may lower the seizure threshold, especially when combined with other medications that increase seizure risk (such as antidepressants or antipsychotics).
- History of substance abuse: If you or a family member has ever misused or been dependent on alcohol, prescription medications, or illegal drugs, you are at increased risk of developing opioid addiction. Inform your doctor honestly about your full history.
- Mental health conditions: Depression, anxiety, personality disorders, or other psychiatric conditions may increase the complexity of opioid management and the risk of misuse.
Tapentadol is a controlled substance opioid. Repeated use can lead to tolerance (needing higher doses for the same effect), physical dependence (experiencing withdrawal symptoms if stopped abruptly), and addiction (compulsive drug-seeking behavior). Even use at prescribed therapeutic doses carries risk. If you believe you are developing dependence, contact your doctor immediately. Do not attempt to stop abruptly on your own.
Tapentadol can cause sleep apnea (pauses in breathing during sleep) and sleep-related hypoxemia (low blood oxygen during sleep). Symptoms may include witnessed breathing pauses during sleep, frequent nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime drowsiness. If you or someone observing you notices these symptoms, contact your doctor, who may consider a dose reduction.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before taking Tapentadol Depot Krka. The following precautions apply:
- Pregnancy: Do not take Tapentadol Depot Krka during pregnancy unless your doctor has specifically instructed you to do so. Prolonged use of opioids during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS) in the newborn. NOWS can be life-threatening if not recognized and treated promptly by a physician. Symptoms in the newborn include irritability, hyperactivity, abnormal sleep patterns, high-pitched crying, tremor, vomiting, diarrhea, and failure to gain weight.
- Labor and delivery: Do not use tapentadol during childbirth, as it can cause dangerously slow or shallow breathing (respiratory depression) in the newborn.
- Breastfeeding: Tapentadol may be excreted in breast milk and could affect the nursing infant. Do not breastfeed while taking this medication.
Driving and Operating Machinery
Tapentadol Depot Krka can cause drowsiness, dizziness, and blurred vision, and may impair your reaction time. These effects are most pronounced when starting treatment, during dose changes, or when combined with alcohol or sedative medications. Do not drive, operate heavy machinery, or perform activities requiring alertness until you know how this medication affects you. Your doctor will advise you on whether it is safe for you to drive.
How Does Tapentadol Depot Krka Interact with Other Drugs?
Drug interactions with tapentadol can be dangerous and even fatal. The dual mechanism of action (opioid agonism and norepinephrine reuptake inhibition) creates interaction potential with a broader range of medications than traditional opioids. It is essential that your doctor and pharmacist know about every medication you take.
Major Interactions (Potentially Life-Threatening)
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| MAO inhibitors (e.g., phenelzine, tranylcypromine, selegiline) | Serotonin syndrome, hypertensive crisis, cardiovascular collapse | Absolutely contraindicated. Do not use within 14 days of MAO inhibitor therapy. |
| Benzodiazepines (e.g., diazepam, lorazepam, alprazolam) | Profound sedation, respiratory depression, coma, death | Avoid combination. If unavoidable, use lowest doses for shortest duration. |
| Other opioids (morphine, codeine, tramadol) | Additive respiratory depression, overdose | Generally avoid. Careful dose adjustment if necessary. |
| Alcohol | Enhanced CNS depression, respiratory depression, fatal overdose | Absolutely avoid alcohol during treatment. |
| Serotonergic drugs (SSRIs, SNRIs, triptans, St. John's Wort) | Serotonin syndrome — agitation, hyperthermia, myoclonus, autonomic instability | Use with extreme caution. Monitor for serotonin syndrome symptoms. |
| Gabapentinoids (gabapentin, pregabalin) | Increased risk of opioid overdose, respiratory depression, death | Use lowest effective doses. Close monitoring required. |
Moderate Interactions
| Drug / Drug Class | Risk | Recommendation |
|---|---|---|
| Sedating antihistamines (e.g., diphenhydramine, promethazine) | Additive sedation, respiratory depression | Use with caution. Monitor for excessive sedation. |
| Barbiturates (e.g., phenobarbital) | Additive CNS depression; phenobarbital may also induce tapentadol metabolism | Avoid if possible. Dose adjustment may be needed. |
| Antipsychotics | Additive sedation, lowered seizure threshold | Monitor closely. Be alert for seizures. |
| Mixed agonists/antagonists (pentazocine, nalbuphine) or partial agonists (buprenorphine) | Reduced efficacy of tapentadol; potential precipitated withdrawal | Avoid combination. May diminish analgesic effect. |
| Strong enzyme inducers (rifampicin, St. John's Wort) | Reduced tapentadol efficacy due to accelerated metabolism | Inform your doctor. Dose adjustment may be needed. |
| Seizure-lowering drugs (certain antidepressants, antipsychotics) | Increased seizure risk | Use with caution. Monitor for seizure activity. |
When combining tapentadol with serotonergic medications, watch for symptoms of serotonin syndrome: involuntary rhythmic muscle contractions, agitation, excessive sweating, tremor, exaggerated reflexes, increased muscle tension, and body temperature above 38°C (100.4°F). Serotonin syndrome is rare but potentially life-threatening. Seek immediate medical attention if you experience these symptoms.
Always inform your healthcare team about all medications you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements such as St. John's Wort. Some combinations that seem harmless can be dangerous when combined with tapentadol.
What Is the Correct Dosage of Tapentadol Depot Krka?
Always take Tapentadol Depot Krka exactly as your doctor or pharmacist has instructed. The guiding principle is to use the lowest effective dose for the shortest necessary duration. Your doctor will individualize the dose based on the severity of your pain, your previous analgesic experience, and your individual sensitivity to the medication.
Adults
Standard Adult Dosing
- Starting dose: 50 mg tapentadol every 12 hours (twice daily)
- Dose adjustments: Your doctor may prescribe a different dose or interval based on your individual needs
- Maximum daily dose: 500 mg (e.g., 250 mg twice daily)
- If you feel the tablets are too strong or too weak, talk to your doctor — do not adjust the dose yourself
Children and Adolescents (6 to 17 years)
Pediatric Dosing
- Dosage is based on the child's age and body weight, as determined by the prescribing physician
- Maximum daily dose: 500 mg (250 mg every 12 hours)
- Children and adolescents with obesity should be monitored carefully; do not exceed recommended maximum doses
- Not suitable for children under 6 years of age
- Children and adolescents with liver or kidney problems should not take these tablets
Elderly Patients
Elderly Dosing (over 65 years)
- Dose adjustment is generally not necessary in elderly patients
- However, excretion of tapentadol may be delayed in some elderly patients, and the doctor may recommend a different dosing interval
- Elderly patients are more susceptible to respiratory depression and should be closely monitored
Patients with Organ Impairment
| Condition | Recommendation |
|---|---|
| Mild hepatic impairment | No dose adjustment necessary |
| Moderate hepatic impairment | Longer dosing interval recommended by your doctor |
| Severe hepatic impairment | Do not use — contraindicated |
| Mild/moderate renal impairment | No dose adjustment necessary |
| Severe renal impairment | Do not use — contraindicated |
How to Take the Tablets
Tapentadol Depot Krka tablets are taken orally (by mouth). Follow these important instructions:
- Swallow whole with a sufficient amount of liquid. Do not crush, chew, break, or dissolve the tablets.
- The tablets can be taken with or without food — food does not affect the medication's efficacy.
- Take the tablets at approximately the same times each day (every 12 hours) for consistent pain relief.
- The tablet shell may occasionally appear in your stool. This is harmless — the active ingredient has already been absorbed.
Crushing, chewing, or breaking the extended-release tablet destroys the controlled-release mechanism and can release the entire dose at once. This can cause a fatal overdose, even in patients who are tolerant to opioids. Always swallow the tablet whole.
Missed Dose
If you forget to take a dose, you will likely notice your pain returning. Do not take a double dose to make up for the missed one. Simply take your next dose at the regular time and continue your usual schedule.
Overdose
If you have taken too much Tapentadol Depot Krka, or if a child has accidentally ingested the medication, seek emergency medical help immediately by calling your local poison control center or emergency services.
Symptoms of overdose may include:
- Pinpoint pupils (miosis)
- Vomiting
- Drop in blood pressure (hypotension)
- Rapid heartbeat (tachycardia)
- Collapse
- Reduced consciousness or coma
- Seizures
- Dangerously slow or shallow breathing or complete respiratory arrest
Respiratory depression is the primary cause of opioid overdose deaths. The opioid antagonist naloxone can reverse respiratory depression caused by tapentadol, but medical supervision is still essential as the effects of naloxone may wear off before the effects of tapentadol, requiring repeated doses.
Stopping Treatment
Do not stop taking Tapentadol Depot Krka suddenly without consulting your doctor. After prolonged use, abrupt discontinuation can cause withdrawal symptoms including:
- Restlessness, watery eyes, runny nose, yawning, sweating, chills
- Muscle aches, dilated pupils, irritability, anxiety
- Back pain, joint pain, weakness, abdominal cramps
- Insomnia, nausea, loss of appetite, vomiting, diarrhea
- Increased blood pressure, increased respiratory rate, increased heart rate
Your doctor will guide you through a gradual dose reduction (tapering) to minimize withdrawal symptoms. The tapering schedule will be individualized based on your dose and duration of use.
What Are the Side Effects of Tapentadol Depot Krka?
Like all medicines, Tapentadol Depot Krka can cause side effects, although not everybody gets them. The side effect profile is consistent with its opioid mechanism of action. Many common side effects improve as your body adjusts to the medication over the first few weeks of treatment.
Allergic reactions (wheezing, difficulty breathing, swelling of eyelids, face, or lips, widespread rash or itching), or breathing that is slower or weaker than expected. The latter is more common in elderly and debilitated patients. These require emergency medical care.
Very Common
May affect more than 1 in 10 people
- Nausea
- Constipation
- Dizziness
- Drowsiness (somnolence)
- Headache
Common
May affect up to 1 in 10 people
- Decreased appetite
- Anxiety, depressed mood, sleep problems, nervousness, restlessness
- Attention disturbance, tremor, involuntary muscle twitching
- Flushing, shortness of breath
- Vomiting, diarrhea, digestive discomfort
- Itching, increased sweating, skin rash
- Feeling of weakness, fatigue, feeling of altered body temperature
- Dry mucous membranes, fluid retention (edema)
Uncommon
May affect up to 1 in 100 people
- Allergic reactions (including angioedema, urticaria, severe anaphylaxis)
- Weight loss, disorientation, confusion, agitation
- Perception difficulties, abnormal dreams, euphoria
- Reduced consciousness, memory impairment, mental impairment
- Fainting (syncope), sedation, balance problems, speech difficulties
- Numbness, abnormal skin sensations (tingling, prickling)
- Visual disturbances, increased/decreased heart rate, palpitations
- Decreased blood pressure, abdominal discomfort, urticaria
- Urinary retention, frequent urination, sexual dysfunction
- Drug withdrawal symptoms, feeling abnormal, irritability
Rare
May affect up to 1 in 1,000 people
- Drug dependence
- Abnormal thinking
- Seizures (epileptic fits)
- Pre-syncope (feeling faint), abnormal coordination
- Respiratory depression (dangerously slow or shallow breathing)
- Impaired gastric emptying
- Feeling of intoxication, feeling of relaxation
Delirium has been reported with unknown frequency. Additionally, patients with chronic pain may have an increased risk of suicidal thoughts and behavior. While certain medications that affect neurotransmitters (such as some antidepressants) can increase this risk, clinical data for tapentadol in humans do not show evidence of increased suicidal risk.
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. Reporting suspected adverse reactions after marketing authorization helps with ongoing monitoring of the medicine's benefit-risk balance.
How Should You Store Tapentadol Depot Krka?
Proper storage of opioid medications is critically important for safety, particularly in households with children or individuals at risk of substance misuse. Tapentadol Depot Krka is supplied in high-density polyethylene (HDPE) containers with child-resistant safety-sealed polypropylene closures. Always ensure the cap is fully closed after each use.
- Keep out of the sight and reach of children. Accidental ingestion by a child can be fatal.
- Do not use after the expiry date stated on the packaging (after "EXP"). The expiry date refers to the last day of that month.
- No special storage conditions are required (no refrigeration needed; store at room temperature).
- Disposal: Do not flush unused medications down the toilet or throw them in household waste. Return unused tablets to your pharmacy for safe disposal. This protects the environment and prevents accidental exposure or diversion.
If you have leftover medication after completing treatment, dispose of it promptly. Keeping unused opioids in the home increases the risk of accidental ingestion, theft, or misuse. Many pharmacies and local authorities offer take-back programs for safe medication disposal.
What Does Tapentadol Depot Krka Contain?
Active Ingredient
Each extended-release tablet contains tapentadol maleate hemihydrate, equivalent to the labeled amount of tapentadol:
- 50 mg tapentadol
- 100 mg tapentadol
- 150 mg tapentadol
- 200 mg tapentadol
- 250 mg tapentadol
Inactive Ingredients (Excipients)
Tablet core: Hypromellose, microcrystalline cellulose, colloidal anhydrous silicon dioxide, and magnesium stearate.
Film coating: Hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol, triacetin. Additional colorants vary by strength: yellow iron oxide (E172) in 100 mg, 150 mg, 200 mg, and 250 mg tablets; red iron oxide (E172) in 150 mg, 200 mg, and 250 mg tablets; black iron oxide (E172) in the 250 mg tablet only.
Tapentadol Depot Krka contains lactose monohydrate as an excipient in the film coating. If you have been told by your doctor that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Tablet Appearance
| Strength | Color | Imprint | Size |
|---|---|---|---|
| 50 mg | White or almost white | T1 | ~16 mm × 8.5 mm |
| 100 mg | Light brownish yellow | T2 | ~16 mm × 8.5 mm |
| 150 mg | Light pink | T3 | ~16 mm × 8.5 mm |
| 200 mg | Light brownish orange | T4 | ~18 mm × 8 mm |
| 250 mg | Pinkish | T5 | ~18 mm × 8 mm |
All tablets are oval (oblong), biconvex, and film-coated, with the imprint on one side. The tablets are available in cartons containing 20 (50 mg only), 30, 60 (2 × 30), or 100 tablets in HDPE containers with child-resistant closures. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions
Tapentadol Depot Krka is prescribed for the management of severe chronic pain in adults and children over 6 years of age when other non-opioid pain medications have proven insufficient. It is an extended-release formulation that provides 12 hours of continuous pain relief per dose. Common conditions for which it may be prescribed include severe chronic musculoskeletal pain, neuropathic pain, and other chronic pain syndromes that require opioid-level analgesia.
Tapentadol is unique among opioids because it has a dual mechanism of action: mu-opioid receptor agonism (like traditional opioids) combined with norepinephrine reuptake inhibition (similar to certain antidepressants). This dual mechanism allows tapentadol to provide effective pain relief through two complementary pathways. Clinical studies suggest that this may result in fewer gastrointestinal side effects (especially constipation and nausea) at equivalent analgesic doses compared to pure mu-opioid agonists like morphine or oxycodone.
The extended-release tablet is designed with a special matrix that slowly releases the medication over 12 hours. If you crush, chew, or break the tablet, you destroy this controlled-release mechanism. The entire dose of tapentadol would then be absorbed rapidly, potentially leading to a massive overdose. This can cause fatal respiratory depression (your breathing stops) even in individuals who are already tolerant to opioids. Always swallow the tablet whole with liquid.
No. Alcohol must be completely avoided while taking Tapentadol Depot Krka. Alcohol is a central nervous system depressant, and combining it with tapentadol can dramatically increase the risk of life-threatening respiratory depression, profound sedation, coma, and death. Even moderate amounts of alcohol can significantly amplify the dangerous effects of opioids. This includes beer, wine, spirits, and alcohol-containing medications or mouthwashes.
If you suspect an overdose, call your local emergency services or poison control center immediately. Symptoms of overdose include pinpoint pupils, vomiting, low blood pressure, rapid heartbeat, loss of consciousness, seizures, and dangerously slow or absent breathing. While waiting for emergency help, try to keep the person awake and breathing. If available, naloxone (an opioid reversal agent) can be administered. Even after naloxone, emergency medical care is still essential.
No, you should not stop taking tapentadol abruptly after prolonged use, as this can trigger withdrawal symptoms including restlessness, watery eyes, runny nose, yawning, sweating, chills, muscle aches, anxiety, insomnia, nausea, vomiting, and diarrhea. Your doctor will create a gradual dose-reduction (tapering) plan tailored to your specific situation. Always discuss any desire to stop treatment with your doctor first.
References
This article is based on the following evidence-based sources:
- European Medicines Agency (EMA). Tapentadol — Summary of Product Characteristics (SmPC). Available at: ema.europa.eu.
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents (2018). Geneva: WHO.
- Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. “Is tapentadol different from classical opioids? A review of the evidence.” British Journal of Pain. 2016;10(4):217–221.
- Tzschentke TM, et al. “Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.” Drugs of Today. 2009;45(7):483–496.
- National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. NICE guideline [NG193]. 2021.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recomm Rep. 2022;71(No. RR-3):1–95.
- Kress HG. “Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally acting analgesics on the horizon?” European Journal of Pain. 2010;14(8):781–783.
- British National Formulary (BNF). Tapentadol monograph. Available at: bnf.nice.org.uk.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specializing in pain medicine, clinical pharmacology, and evidence-based medicine.
iMedic Medical Editorial Team — specialists in pharmacology and pain medicine with clinical and academic expertise.
iMedic Medical Review Board — independent panel of board-certified physicians reviewing all content against international guidelines (EMA, WHO, FDA, NICE, BNF).
Editorial Standards: All medication information follows the GRADE evidence framework and is cross-referenced with the European Medicines Agency SmPC, WHO guidelines, and current peer-reviewed literature. No commercial funding or pharmaceutical sponsorship influences our content. Read more about our editorial standards.